Ina Jochmans1, Steffen Fieuws, Diethard Monbaliu, Jacques Pirenne. 1. 1 Laboratory of Abdominal Transplant Surgery, Department of Microbiology and Immunology, KU Leuven, Leuven, Belgium. 2 Abdominal Transplant Surgery, University Hospitals Leuven, Leuven, Belgium. 3 Interuniversity Centre for Biostatistics and Statistical Bioinformatics, Department of Public Health, KU Leuven, Leuven, Belgium.
Abstract
BACKGROUND: The Model of Early Allograft Function (MEAF) grades the severity of liver graft dysfunction. Unlike the categorical early allograft dysfunction (EAD) classification, MEAF is a continuous score, based on bilirubin, international normalized ratio, and alanine aminotransferase within 3 days posttransplant. METHODS: Multivariable regression models were used to validate the MEAF score in 660 liver-only transplants performed between 2000 and 2014. MEAF performance for prediction of transplant survival was compared with that of EAD in univariable and multivariable models by means of Harrell's c-indices, integrated discrimination improvement, and net reclassification improvement. RESULTS: Median donor and recipient age was 52 years (interquartile range [IQR], 41-62 years) and 58 years (IQR, 50-64 years), respectively. Model for End-Stage Liver Disease score was 15 (IQR, 11-21); cold ischemia time, 8.0 hours (IQR, 6.4-9.7 hours); MEAF, 4 (IQR, 3-6). EAD occurred in 182 (27.6%) cases. Transplant survival was 93%, 90%, and 88% at 3, 6, and 12 months. Both MEAF and EAD were independent predictors of transplant survival within 3, 6, and 12 months. MEAF outperformed EAD as predictor of transplant survival, either when used as a standalone parameter or when corrected for additional independent predictors of transplant survival. CONCLUSIONS: MEAF is a more accurate predictor of transplant loss than the commonly used EAD classification. As a continuous score grading graft dysfunction, MEAF provides additional, granulated information that could be used both clinically and as a surrogate endpoint of transplant survival in clinical trials.
BACKGROUND: The Model of Early Allograft Function (MEAF) grades the severity of liver graft dysfunction. Unlike the categorical early allograft dysfunction (EAD) classification, MEAF is a continuous score, based on bilirubin, international normalized ratio, and alanine aminotransferase within 3 days posttransplant. METHODS: Multivariable regression models were used to validate the MEAF score in 660 liver-only transplants performed between 2000 and 2014. MEAF performance for prediction of transplant survival was compared with that of EAD in univariable and multivariable models by means of Harrell's c-indices, integrated discrimination improvement, and net reclassification improvement. RESULTS: Median donor and recipient age was 52 years (interquartile range [IQR], 41-62 years) and 58 years (IQR, 50-64 years), respectively. Model for End-Stage Liver Disease score was 15 (IQR, 11-21); cold ischemia time, 8.0 hours (IQR, 6.4-9.7 hours); MEAF, 4 (IQR, 3-6). EAD occurred in 182 (27.6%) cases. Transplant survival was 93%, 90%, and 88% at 3, 6, and 12 months. Both MEAF and EAD were independent predictors of transplant survival within 3, 6, and 12 months. MEAF outperformed EAD as predictor of transplant survival, either when used as a standalone parameter or when corrected for additional independent predictors of transplant survival. CONCLUSIONS: MEAF is a more accurate predictor of transplant loss than the commonly used EAD classification. As a continuous score grading graft dysfunction, MEAF provides additional, granulated information that could be used both clinically and as a surrogate endpoint of transplant survival in clinical trials.
Authors: Vittorio Cherchi; Luigi Vetrugno; Giovanni Terrosu; Victor Zanini; Marco Ventin; Riccardo Pravisani; Francesco Tumminelli; Pier Paolo Brollo; Erica Boscolo; Roberto Peressutti; Dario Lorenzin; Tiziana Bove; Andrea Risaliti; Umberto Baccarani Journal: PLoS One Date: 2021-08-27 Impact factor: 3.240
Authors: Tao Lv; LingXiang Kong; Jiayin Yang; Hong Wu; Tianfu Wen; Li Jiang; Jian Yang Journal: Medicine (Baltimore) Date: 2020-01 Impact factor: 1.817
Authors: Aki Uutela; Ilkka Helanterä; Karl Lemström; Arie Passov; Simo Syrjälä; Fredrik Åberg; Heikki Mäkisalo; Arno Nordin; Marko Lempinen; Ville Sallinen Journal: BMJ Open Date: 2020-11-16 Impact factor: 2.692
Authors: Riccardo Pravisani; Paolo De Simone; Damiano Patrono; Andrea Lauterio; Matteo Cescon; Enrico Gringeri; Michele Colledan; Fabrizio Di Benedetto; Fabrizio di Francesco; Barbara Antonelli; Tommaso Maria Manzia; Amedeo Carraro; Marco Vivarelli; Enrico Regalia; Giovanni Vennarecci; Nicola Guglielmo; Manuela Cesaretti; Alfonso Wolfango Avolio; Maria Filippa Valentini; Quirino Lai; Umberto Baccarani Journal: Updates Surg Date: 2021-04-01